Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
Rhea-AI Summary
Femasys Inc. (NASDAQ: FEMY) has launched its new FemSperm Insemination Prep Kit, completing the sperm preparation component of their FemSperm product line. This development enables gynecologists to perform FemaSeed Intratubal Insemination procedures directly in their offices.
The kit works in conjunction with the FemSperm Setup kit to optimize sperm preparation for FemaSeed procedures. This innovation targets the estimated 10 million U.S. women facing infertility, offering a more accessible fertility treatment option through gynecologist offices, as an alternative to traditional IVF centers which only perform about 200,000 transfer cycles annually.
FemaSeed has demonstrated superior efficacy, achieving more than double the pregnancy rates of intrauterine insemination (IUI) in cases of low male sperm count during its pivotal trial. The treatment is currently authorized in multiple markets including the U.S., Europe, UK, Canada, Israel, Australia, and New Zealand.
Positive
- Clinical trials showed more than double pregnancy rates compared to IUI for low sperm count cases
- Expansion of market reach through tens of thousands of gynecologist offices
- Product addresses large untapped market of 10 million U.S. women facing infertility
- Multi-market authorization including U.S., Europe, UK, Canada, Israel, Australia and New Zealand
Negative
- Current IVF market penetration shows limited reach with only 200,000 transfer cycles annually
News Market Reaction – FEMY
On the day this news was published, FEMY gained 2.26%, reflecting a moderate positive market reaction. Argus tracked a peak move of +8.7% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $376K to the company's valuation, bringing the market cap to $17M at that time.
Data tracked by StockTitan Argus on the day of publication.
-- Following the Setup Kit, the Insemination Kit completes the sperm preparation portion of FemSperm enabling gynecology call point activation to drive revenue growth --
ATLANTA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced the introduction of its FemSperm Insemination Prep Kit, designed to fully enable gynecologists to perform FemaSeed Intratubal Insemination. The kit includes customized components, such as sperm washing for specific use with the FemSperm Setup kit to optimize sperm preparation for FemaSeed procedures.
This offering marks a key milestone in advancing Femasys’ gynecology-focused commercialization strategy for the FemaSeed platform and supports entry into the large, underserved fertility market. By providing a streamlined, in-office solution, the company is creating the foundation for gynecologist-driven adoption of FemaSeed as a first-step fertility treatment, broadening patient access to alternatives ahead of IVF and strengthening its long-term revenue growth strategy.
“The availability of the FemSperm Insemination Prep Kit completes the sperm preparation process required for FemaSeed and enables tens of thousands of gynecologists to offer our first-step fertility solution directly within their practices,” said Kathy Lee-Sepsick, Chief Executive Officer and Founder of Femasys Inc. “Until now, most gynecologists have lacked a convenient method for sperm preparation. With an estimated 10 million U.S. women facing infertility and only about 200,000 IVF transfer cycles performed each year, the vast majority never reach a referral infertility center. By removing this barrier, we are making fertility care more accessible where women already receive care, at their gynecologist’s office.”
With the availability of the FemSperm product family, gynecologists can now perform sperm preparation and offer FemaSeed Intratubal Insemination directly within their practices. FemaSeed is a next-generation artificial insemination solution that enhances natural fertilization by delivering sperm precisely to the fallopian tube, the site of conception. Positioned as a true first step in the fertility journey, FemaSeed offers a safe, accessible, and cost-effective alternative to intrauterine insemination (IUI). In its pivotal trial, FemaSeed achieved more than double the pregnancy rates of IUI in cases of low male sperm count.1 As an affordable, less invasive, lower-risk option before IVF, FemaSeed is authorized for use in the U.S., Europe, UK, Canada, Israel, Australia and New Zealand. Learn more at www.femaseed.com.
About Femasys
Femasys is a leading biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women worldwide through its broad, patent-protected portfolio of novel, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed® Intratubal Insemination, a groundbreaking first-step infertility treatment and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data demonstrates FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.1
FemBloc® permanent birth control is the first and only non-surgical, in-office alternative to centuries-old surgical sterilization that received full regulatory approval in Europe in June of 2025, United Kingdom in August 2025, and New Zealand in September 2025. Commercialization of this highly cost-effective, convenient and significantly safer approach will be completed through strategic partnerships in select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going.
Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
References
1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.
2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
David Gutierrez, Dresner Corporate Services, (312) 780-7204, dgutierrez@dresnerco.com
Nathan Abler, Dresner Corporate Services, (714) 742-4180, nabler@dresnerco.com
FAQ
What is the new FemSperm Insemination Prep Kit by Femasys (NASDAQ: FEMY)?
How effective is FemaSeed compared to traditional IUI treatment?
What markets has Femasys received authorization for FemaSeed?
How many women could potentially benefit from Femasys's fertility treatment?
What advantages does FemaSeed offer over traditional fertility treatments?
